

The DUAL-ACS Trial

Duration of Dual Anti-Platelet Therapy in Acute Coronary Syndrome

PURPOSE: To evaluate the optimal duration of dual antiplatelet therapy (DAPT), comparing 3-month versus 12-month regimens, following myocardial infarction (MI)

STUDY DESIGN: International, open-label, 1:1 randomized, active controlled, pragmatic trial, N=5052

KEY TAKEAWAYS: A 3-month course of DAPT following MI may offer comparable benefits to longer treatment durations, while potentially reducing the risks associated with prolonged therapy.

	3-Months DAPT	12-Months DAPT	HR (95% CI)	P value
Primary outcome				
All-cause mortality	2.7%	3.4%	0.78 (0.57-1.07)	0.1232
RESULTS: There were no significant differences in all-cause mortality between 3 and 12 months of DAPT, with a trend for lower rates of fatal or major bleeding.				